AOD-9604 drug interactions: what actually gets checked

Last updated 2026-07-25

Does AOD-9604 interact with other medications?

Nobody has run a formal drug interaction study on AOD-9604 in humans. That's the honest answer, and it's worth sitting with for a second before going further. What we do have is a body of small early-phase trials from the 2000s (often described under the heading "Gateways to clinical trials") that tracked AOD-9604 as an obesity candidate, plus later reviews of peptide safety in sports and orthopedic medicine ^[1][2]. None of these were designed to test co-administration with statins, blood pressure medication, insulin, thyroid hormone, or anything else a typical patient might be taking. So when someone asks "can I take AOD-9604 with my blood pressure pills," the true answer is: nobody has checked that combination in a trial, full stop. What we can reason about is mechanism. AOD-9604 is a synthetic fragment of human growth hormone, amino acids 176-191, engineered specifically to isolate the fat-metabolizing (lipolytic) piece of the HGH molecule while dropping the growth-promoting piece ^[3]. That design intent matters for interaction risk, because most of the serious HGH interaction concerns (insulin resistance, fluid retention, interactions with diabetes medication) trace back to the growth-hormone-receptor and IGF-1 side of the molecule, not the fat-metabolism side. If AOD-9604 truly does not activate that axis the way it was designed not to, its interaction profile should look different from full-length HGH. Should. Not proven.

Does AOD-9604 raise IGF-1 or affect insulin like HGH does?

This is the single most load-bearing question for interaction risk, because IGF-1 elevation and insulin resistance are where real HGH creates most of its drug interaction problems (with diabetes medications especially). The fragment was specifically designed to retain the fat-metabolizing region of the HGH molecule (amino acids 176-191) without the region responsible for growth and IGF-1 stimulation ^[3]. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604's development as an anti-obesity candidate built around this metabolic fragment, distinct from the growth-promoting regions of full HGH ^[3]. That's the rationale, and it's a reasonable one on paper. But 'designed to avoid IGF-1 stimulation' and 'confirmed in large human trials to never raise IGF-1 under real-world dosing' are two different claims, and only the first one has solid backing. If you are diabetic, prediabetic, or on any insulin-sensitizing medication, this is exactly the gap you want your prescriber to know about before you start anything.

Is AOD-9604 safe to combine with GLP-1 drugs like semaglutide or tirzepatide?

There is no published trial testing AOD-9604 stacked with semaglutide, tirzepatide, or any GLP-1 receptor agonist. People do this combination informally because the theory sounds appealing (GLP-1 for appetite, AOD-9604 for fat metabolism), but appealing theory is not clinical evidence. GLP-1 drugs carry their own well-documented interaction and side effect profile, most notably with insulin and sulfonylureas (hypoglycemia risk), and with anything that slows gastric emptying. Layering an unstudied peptide with an unclear mechanism on top of that doesn't add data, it adds unknowns. If your reason for wanting AOD-9604 is disappointment with GLP-1 results or side effects, that's a conversation to have with a prescriber, not a reason to self-stack. For a full comparison of AOD-9604 against a related growth-hormone-axis peptide with a cleaner human evidence base, see aod 9604 vs tesamorelin.

Does AOD-9604 interact with anesthesia or surgery?

There's no clinical data on AOD-9604 and surgical anesthesia specifically. The general practice with unregulated peptides and supplements before surgery is conservative: stop anything without an established surgical safety record for at least a week or two before an operation, and tell your surgical team about it regardless of whether you think it matters. This isn't specific proof of a problem with AOD-9604. It's a reflection of the fact that anesthesiologists can't plan around a substance with no published interaction data, so the safest move is disclosure and a pause, not silence.

Can AOD-9604 be combined with other peptides like BPC-157 or CJC-1295?

This is common in practice, uncommon in evidence. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides used in orthopedic and musculoskeletal contexts, including the challenges of applying them clinically given gaps in regulation and standardized dosing ^[1]. A companion 2026 review in Sports Medicine specifically addresses the safety and efficacy of approved versus unapproved peptide therapies used for musculoskeletal injuries and athletic performance, flagging the uneven evidence quality across this category ^[2]. Neither review reports a specific AOD-9604 plus BPC-157 or AOD-9604 plus CJC-1295 interaction study, because that study doesn't exist yet. What both reviews do make clear is that the peptide space generally suffers from inconsistent manufacturing, unclear dosing standards, and thin safety data outside of the handful of peptides that have gone through FDA review. Stacking two peptides that individually lack strong interaction data doesn't cancel the uncertainty out. It compounds it.

Does AOD-9604 interfere with drug testing or anti-doping screens?

Here's one place we do have real, direct data. A 2013 study in Drug Testing and Analysis tested whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test anti-doping labs use to detect growth hormone doping, and found it does not influence that assay ^[4]. In plain terms: AOD-9604 doesn't show up as HGH and doesn't mask it on that specific test. That doesn't mean AOD-9604 is invisible to all doping controls. Separate analytical work has focused specifically on detecting AOD-9604 itself in urine and blood, including methods built around direct urine injection combined with liquid chromatography and ion mobility mass spectrometry for peptides under 2 kDa, a size range AOD-9604 falls into ^[5]. Broader reviews of doping detection methodology for peptide drugs and analogs describe AOD-9604 as one of the target compounds analytical chemists have specifically built assays to catch ^[6][7]. If you're competing in a tested sport, assume detectable, not assume safe.

What does the human trial evidence actually say about AOD-9604's effectiveness?

This is the part that matters most, and it's the part that gets buried most often in marketing copy. AOD-9604 went through a series of human obesity trials in the 2000s, tracked in the pharmaceutical pipeline literature under headings like "Gateways to clinical trials" across 2003 and 2005 ^[8][9][10]. A 2004 review in Current Opinion in Investigational Drugs specifically covers AOD-9604's metabolic profile as an obesity drug candidate ^[3], and a 2006 review of obesity drugs in clinical development places it among a wider field of candidates being tested at the time ^[11]. The honest summary: the weight-loss results from these trials did not separate convincingly from placebo. AOD-9604 never secured FDA approval as an obesity treatment, and it does not appear in the FDA's Drugs@FDA database of approved drug products ^[12]. That absence is not a paperwork technicality. It reflects a drug development program that ran its course through early-phase human trials and did not produce results strong enough to justify continued approval-track investment. Anyone selling you AOD-9604 on the strength of "clinical trials showed fat loss" is quoting the intent of those trials, not their outcome. For the full breakdown of what the fragment does and doesn't do mechanistically, read what does AOD-9604 actually do.

Is it legal to buy AOD-9604 for personal use in the US?

AOD-9604 is not FDA-approved for any human use, and it does not appear on the FDA's current bulk drug substances list for 503A pharmacy compounding ^[13] or the list for 503B outsourcing facility compounding ^[14]. Those two lists, published under 21 CFR 216.23 and 216.24, are what determine whether a compounding pharmacy can legally prepare a substance for an individual patient prescription ^[15][16]. Pharmacy compounding itself is legal under federal law when it meets the conditions in 21 U.S.C. 353a, including a valid patient-specific prescription and compliance with USP standards . But compounding a substance not on the approved bulks list, or marketing a peptide with implied therapeutic claims (weight loss, anti-aging) that go beyond what's approved, runs into FDA's "intended use" framework under 21 CFR 201.128, which looks at claims and marketing context, more than the physical product, to determine regulatory status . Practically, this means AOD-9604 sold as "research use only" occupies a legal gray zone. It is not illegal to possess in most circumstances, but no legitimate compounding pharmacy can legally dispense it for human use as a weight-loss drug given its absence from the bulks lists. If you want a provider-reviewed path rather than an unregulated research-chemical vendor, see best place to buy AOD-9604, which covers how AOD-9604 Co routes buyers through provider review rather than shipping product directly.

What about interactions with alcohol, caffeine, or supplements?

No published data addresses AOD-9604 combined with alcohol, caffeine, or common supplements specifically. This isn't a case where we're withholding a known risk, it's simply an unstudied combination like most others on this list. General peptide handling advice applies: heavy alcohol use complicates any injectable therapy by affecting liver metabolism and immune response at the injection site, and stacking multiple stimulant or fat-loss supplements (caffeine, yohimbine, ephedrine-adjacent compounds) with an unregulated peptide multiplies the number of unknowns your body is managing at once, even if none of them interact directly.

Who should avoid AOD-9604 or check with a prescriber first?

Given the total absence of interaction trials, a cautious approach makes sense for anyone with an existing endocrine condition (diabetes, thyroid disease, pituitary disorders), anyone pregnant or breastfeeding, anyone with active cancer or a cancer history (given the general caution around growth-hormone-axis peptides and cell proliferation signaling), and anyone already on multiple prescription medications where an unstudied variable is harder to isolate if something goes wrong. For the full list of who should not use this peptide and why, see AOD-9604 contraindications. For the broader side effect picture beyond interactions specifically, see AOD-9604 side effects.

How should I actually approach AOD-9604 if I still want to try it?

If you've read all of this and still want to proceed, do it through a provider-reviewed channel rather than an anonymous research-chemical site. A prescriber who knows your full medication list can flag theoretical concerns (diabetes drugs, thyroid medication, anything metabolized heavily by the liver) even in the absence of formal trial data, and can watch for early warning signs rather than leaving you to self-monitor. AOD-9604 Co reviews sourcing through this lens: provider review first, fulfillment through a named pharmacy partner, not a blind cart checkout. That doesn't erase the trial record gap. It just means someone qualified is in the loop if something unexpected happens. Correct injection technique also matters for minimizing local site reactions that can complicate how you interpret any symptom you experience. See AOD-9604 how to inject for that.

AOD-9604 vs better-evidenced options: what should you actually pick?

If your goal is fat loss backed by real Phase 3 human trial data, AOD-9604 is not where that evidence lives. Tesamorelin, for comparison, is FDA-approved specifically for reducing excess abdominal fat in HIV-associated lipodystrophy, a much narrower indication but one with actual regulatory approval behind it, meaning it went through trials that met FDA's efficacy bar for that specific population.

See the full mechanism and evidence comparison at aod 9604 vs tesamorelin.

Frequently asked questions

Can AOD-9604 be taken with blood pressure medication?

No study has tested this combination. AOD-9604 is designed to avoid the growth-hormone-receptor pathway that causes fluid retention in full HGH, which is the main mechanism linking HGH to blood pressure changes, but that design intent hasn't been confirmed in a formal interaction trial ^[1]. Tell your prescriber before combining them.

Does AOD-9604 affect blood sugar or interact with insulin?

There's no published human trial testing AOD-9604 alongside insulin or oral diabetes medication. It was engineered to exclude the region of the HGH molecule linked to insulin resistance ^[1], but that's a design rationale, not confirmed clinical safety data. Diabetics should treat this as an unknown and involve a prescriber.

Is AOD-9604 detectable in doping tests?

Yes, it can be detected through specific analytical methods built to catch peptides under 2 kDa, including direct urine injection with liquid chromatography and ion mobility mass spectrometry ^[5]. It does not, however, interfere with or trigger the standard WADA hGH isoform immunoassay ^[4].

Can I stack AOD-9604 with BPC-157 safely?

No dedicated interaction study exists for this combination. Broader peptide safety reviews note inconsistent manufacturing and thin interaction data across the unapproved peptide category generally ^[2][3], so stacking two unstudied peptides adds uncertainty rather than removing it.

Did AOD-9604 actually work in human obesity trials?

The weight-loss results from AOD-9604's human obesity trials in the 2000s did not separate convincingly from placebo ^{[1][8][9][10]}. It never gained FDA approval and does not appear in the FDA's Drugs@FDA database ^[12]. That's the central fact anyone considering it should know.

Is AOD-9604 legal to buy in the US?

It's not FDA-approved and isn't on the FDA's 503A or 503B bulk drug substance lists that govern legal pharmacy compounding ^[13][14]. It occupies a legal gray zone typically sold as research use only; legitimate compounding pharmacies cannot legally dispense it as an approved human weight-loss drug.

Should I stop AOD-9604 before surgery?

There's no anesthesia interaction data for AOD-9604 specifically. The conservative, standard approach with any unregulated peptide is to stop it one to two weeks before a scheduled surgery and disclose its use to your surgical and anesthesia team regardless.

Does AOD-9604 interact with GLP-1 drugs like semaglutide?

No trial has tested this combination. GLP-1 drugs have their own established interaction profile, particularly hypoglycemia risk with insulin or sulfonylureas. Adding an unstudied peptide on top introduces new unknowns rather than resolving side effects or plateaus from the GLP-1 drug alone.

Why isn't there more human interaction data on AOD-9604?

AOD-9604's clinical development stopped at early-phase obesity trials in the mid-2000s after results failed to clearly beat placebo ^{[1][8][9][10]}. Drugs that don't advance to later trial phases or approval rarely get formal interaction studies, since those studies are typically funded as part of continued regulatory approval pathways.

Can AOD-9604 be combined with tesamorelin?

No published study tests this combination. Tesamorelin is FDA-approved for a specific indication (HIV-associated lipodystrophy) with established prescribing data, while AOD-9604 has no approval and no interaction studies. Combining an approved drug with an unstudied one should go through a prescriber, not be self-directed.

Is AOD-9604 safe for someone with thyroid disease?

There's no specific data on AOD-9604 and thyroid conditions or thyroid medication. Given the general caution around unstudied compounds interacting with endocrine conditions, anyone with thyroid disease should discuss AOD-9604 with a prescriber before starting rather than assuming safety by default.

What's the biggest interaction risk with AOD-9604 in practice?

It isn't one specific drug interaction, since none have been formally documented. The bigger practical risk is unknown product quality from unregulated sourcing, since AOD-9604 sold as research-use-only product isn't subject to the manufacturing standards that apply to FDA-approved drugs or properly compounded 503A/503B substances ^[13][14].

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004), PMID 15134286: AOD-9604's metabolic profile and design as an HGH fragment (176-191) intended to isolate fat-metabolizing activity from growth-promoting activity
2. PubMed, JAAOS Global Research & Reviews (2026), PMID 41490200: Review of therapeutic peptides in orthopedics noting regulatory and standardization challenges across the peptide category
3. PubMed, Sports Medicine (2026), PMID 41966639: Safety and efficacy review of approved versus unapproved peptide therapies for musculoskeletal injuries and athletic performance
4. PubMed, Drug Testing and Analysis (2013), PMID 24124033: AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing
5. PubMed, Journal of Separation Science (2016), PMID 26578461: Analytical method using direct urine injection, liquid chromatography, and ion mobility mass spectrometry to screen peptides under 2 kDa
6. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014), PMID 24906629: Analytical approaches developed for detecting emerging therapeutic peptides including AOD-9604 in doping controls
7. PubMed, Expert Review of Proteomics (2014), PMID 25382550: Review of detection methods for peptidic drugs and analogs, including AOD-9604, in sports doping controls
8. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003), PMID 14685303: Tracking of AOD-9604 through early human obesity clinical trials
9. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003), PMID 14571286: Tracking of AOD-9604 through early human obesity clinical trials
10. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005), PMID 15834452: Continued tracking of AOD-9604 clinical trial progress through 2005
11. PubMed, Current Opinion in Investigational Drugs (2006), PMID 16625817: AOD-9604 listed among obesity drug candidates in clinical development as of 2006
12. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product
13. eCFR, 21 CFR 216.23 (503A Bulks List): AOD-9604 is not on the FDA's approved bulk drug substances list for 503A pharmacy compounding
14. eCFR, 21 CFR 216.24 (503B Bulks List): AOD-9604 is not on the FDA's approved bulk drug substances list for 503B outsourcing facility compounding
15. Cornell Law, 21 U.S.C. 353a: Legal conditions under which pharmacy compounding is permitted, including a valid patient-specific prescription
16. eCFR, 21 CFR 201.128: FDA's intended use framework determines regulatory status based on marketing claims, more than the physical substance